EUVIMEDEUVIMED entdecken
Crossref

Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database

Davide Rozza, Elisabetta Poluzzi, Ippazio Cosimo Antonazzo, Angela Boccia, Marco Paccini, Fortuna Gallucci, Domenico Ponticelli, Giulio Geraci, Fernando Agüero, Giampiero Mazzaglia, Lorenzo Giovanni Mantovani, Emanuel Raschi und 1 weitere

Clinical Drug Investigation · 2026-11 · 46 (11) · 1327-1339

DOI: 10.1007/s40261-026-01602-7 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Drug Investigation, online erschienen am 10.10.2026. Verfasst von Davide Rozza und 12 weiteren Autor:innen. Beteiligte Einrichtung: Center for Public Health Research, University of Milan-Bicocca, Monza, Italy. Hauptthemen laut MEDLINE: Pre-Exposure Prophylaxis, Anti-HIV Agents, Adverse Drug Reaction Reporting Systems, HIV Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective As human immunodeficiency virus (HIV) pre-exposure prophylaxis (PrEP) use expands, real-world post-marketing safety evidence remains limited, particularly regarding potential formulation-specific adverse-event patterns across oral and long-acting agents. We aimed to characterise the post-marketing safety profiles of FDA-approved PrEP drugs using the FDA Adverse Event Reporting System (FAERS).

Methods

We conducted a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) data from 2012 to 2024. Individual Case Safety Reports (ICSRs) listing emtricitabine/tenofovir disoproxil fumarate (FTC/TDF), emtricitabine/tenofovir alafenamide (FTC/TAF) or cabotegravir (CAB) as suspected PrEP drugs were included. Two comparator groups were used: all non-PrEP ICSRs and ICSRs involving non-PrEP HIV drugs. Disproportionality was evaluated at the MedDRA high-level term (HLT) level using reporting odds ratios and 95% confidence intervals (CIs), identifying signals of disproportionate reporting (SDRs) with a lower bound of the 95%CIs > 1. Sensitivity analyses explored sex, reporter type, and indication.

Results

We identified 3201 PrEP-related ICSRs (FTC/TDF: 2688; FTC/TAF: 463; CAB: 50), predominantly involving young adult males. FTC/TDF exhibited a broad pattern of SDRs—including renal/metabolic abnormalities, muscular signals, mucosal disorders and some previously under-characterised signals—many of which attenuated when using HIV-treated comparators. FTC/TAF showed a narrower, highly consistent pattern dominated by hepatobiliary and metabolic monitoring procedures, renal function evaluations and neurosensory disturbances. CAB showed specific, reproducible signals for injection-site, dermatologic and procedure-related events.

Conclusions

PrEP agents display distinct, formulation-specific and reproducible safety patterns in FAERS. Comparator choice substantially influences the detection and interpretation of SDRs and can help distinguish reproducible formulation-related reporting patterns from findings that may be driven by the clinical and reporting context. These insights highlight priority areas for future research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-Exposure ProphylaxisAnti-HIV AgentsAdverse Drug Reaction Reporting SystemsHIV InfectionsHumansUnited StatesDatabases, FactualUnited States Food and Drug AdministrationTenofovirEmtricitabine

Substanzen

Anti-HIV AgentsTenofovirEmtricitabine

Autor:innen und Institutionen

  • Center for Public Health Research, University of Milan-Bicocca, Monza, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Department of Environmental and Prevention Sciences, University of Ferrara, Ferrara, Italy. ippazio.antonazzo@unife.it.
  • Clinica Montevergine SpA, Mercogliano, AV, Italy.
  • Department of Medicine and Surgery, "Kore" University of Enna, Enna, Italy.
  • Internal Medicine Unit, Hospital Umberto I, ASP Enna, Enna, Italy.

Zitieren

APA

Rozza, D., Poluzzi, E., Antonazzo, I. C., Boccia, A., Paccini, M., Gallucci, F., Ponticelli, D., Geraci, G., Agüero, F., Mazzaglia, G., Mantovani, L. G., Raschi, E., & Ferrara, P. (2026). Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database. Clinical Drug Investigation, 46(11), 1327-1339. https://doi.org/10.1007/s40261-026-01602-7

Vancouver

Rozza D, Poluzzi E, Antonazzo IC, Boccia A, Paccini M, Gallucci F, et al. Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database. Clinical Drug Investigation. 2026;46(11):1327-1339. doi:10.1007/s40261-026-01602-7

BibTeX
@article{Rozza2026,
  author = {Rozza, Davide and Poluzzi, Elisabetta and Antonazzo, Ippazio Cosimo and Boccia, Angela and Paccini, Marco and Gallucci, Fortuna and Ponticelli, Domenico and Geraci, Giulio and Agüero, Fernando and Mazzaglia, Giampiero and Mantovani, Lorenzo Giovanni and Raschi, Emanuel and Ferrara, Pietro},
  title = {Formulation-Specific Safety Issues of HIV Pre-exposure Prophylaxis Drugs: A Disproportionality Analysis of the FAERS Database},
  journal = {Clinical Drug Investigation},
  year = {2026},
  volume = {46},
  number = {11},
  pages = {1327--1339},
  doi = {10.1007/s40261-026-01602-7}
}
Kostenlos starten →